Weekly intramuscular (250 mg/week) or subcutaneous (275 mg/week) injections of 17-hydroxyprogesterone caproate (17-OHPC) is the only treatment option for the prevention of preterm birth in women with a prior history of preterm delivery.The objective of the current study was to determine the relative distribution of 17-OHPC in selected tissues in adult female SD rats after IM (oily formulation or solution), IV (solution), PO (solution), or intravaginal (suppository) administration.Plasma, uterus, adipose, and liver samples were collected at various times and analysed by LC-MS-MS.The highest concentrations of 17-OHPC were observed in the adipose tissue, after IM (oily formulation), and intravaginal administration.Substantial concentrations of 17-OHPC were also observed in the uterus after IM, intravaginal and IV administration.17-OHPC was not detected in the liver and in any of the tissues tested after PO administration.17-OHPC levels in plasma after intravaginal suppository administration were low despite substantial concentrations in the adipose and the uterus.The distribution of 17-OHPC depends on the formulation, the route of administration, and the sampling time.Low systemic concentrations and substantial distribution in the tissues of interest after intravaginal administration warrants future studies to evaluate the potential of the daily intravaginal route of administration of 17-OHPC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/00498254.2023.2201348 | DOI Listing |
EClinicalMedicine
November 2024
Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Biotherapeutics are among the therapeutics that have revolutionized standard inflammatory bowel disease (IBD) treatment, which was previously limited to mesalamine, 5-aminosalicylic acid, corticosteroids, and classical immunosuppressants. Self-administrable biotherapeutics for IBD would enable home-based treatment and reduce the burden on medical infrastructure. Self-administration is made possible through subcutaneous injectable, oral, and rectal dosage forms.
View Article and Find Full Text PDFEmerg Med Australas
February 2025
Gifted Mathematics Program, Montfort College, Chiang Mai, Thailand.
Objective: The present study aimed to compare time to effective pain relief between diclofenac 75 mg intramuscular (IM) and tramadol 50 mg intravenous (IV) for ED patients with acute renal colic.
Methods: A randomised, double-blinded, sham-controlled, superiority trial was conducted. Patients diagnosed with acute renal colic (hydronephrosis and/or stone visualisation on point-of-care ultrasound) in the ED were randomly assigned to receive an IM injection of 75 mg of diclofenac or IV tramadol 50 mg.
JBI Evid Synth
January 2025
School of Nursing of the University of Minho, Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (Esenfc), Coimbra, Portugal.
Objective: The objective of this review will be to evaluate the effect of prior aspiration versus non-aspiration during intramuscular injection on the occurrence of adverse effects in adult patients.
Introduction: Aspiration is a procedure conducted prior to the administration of intramuscular medications that aims to ensure that the needle tip is inserted in the proper place. Although aspiration is a common procedure, questions have been raised about adverse effects.
Immunopharmacol Immunotoxicol
February 2025
Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Septic shock involves severe systemic inflammatory reaction toward various invading species, such as microorganisms and microbial toxins. Such a response is complicated and characterized as being a dynamic and time-dependent phenomenon. During this response, a significant amount of pro-inflammatory cytokines may be produced, causing a rapid death rate in septic victims and occasionally leading to apoptosis of immune cells within the first hours of septic reaction.
View Article and Find Full Text PDFHinyokika Kiyo
December 2024
The Department of Urology, Morinomiya Hospital.
We examined the efficacy and adverse effects of low-dose intravesical Bacillus Calmette-Guérin (BCG) therapy in patients with non-muscle-invasive bladder cancer. Patients who underwent intravesical BCG therapy (n=176 ; 198 courses) at our hospital between April 2012 and December 2022 were enrolled. After assigning patients to either the low-dose or regular-dose (40 or 80 mg of BCG Tokyo 172 strain) groups, treatment efficacy and incidence of adverse events were compared.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!